

PorA Variable Regions of *Neisseria meningitidis*

Joanne E. Russell,*† Keith A. Jolley,* Ian M. Feavers,† Martin C. J. Maiden,* and Janet Sukert†

Subtypes, defined by variation in the outer membrane protein PorA, are an integral part of the characterization scheme for *Neisseria meningitidis*. Identification of these variants remains important as the PorA protein is a major immunogenic component of several meningococcal vaccines under development, and characteristics of PorA are used to provide detailed epidemiologic information. Historically, serosubtypes have been defined by reactivity with a set of monoclonal antibodies. However, nucleotide sequence analyses of *porA* genes have established that the panel of serosubtyping monoclonal antibodies is not exhaustive, and many *porA* variants cannot be detected. In addition, the nomenclature system used to define subtypes is inadequate. We examined all available nucleotide sequences of the *porA* VR1 and VR2 regions to identify and define subtype families. A revised nomenclature scheme, compatible with the previous serologic nomenclature scheme, was devised. A Web-accessible database describing this nomenclature and its relationship to previous schemes was established (available from: <http://neisseria.org/nm/typing/pora>).

Neisseria meningitidis is a major cause of bacterial meningitis and septicemia worldwide (1). In the absence of a comprehensive vaccine against this organism, the characterization of its variable surface antigens is important for epidemiologic monitoring and vaccine development (2). The serologic characterization scheme for meningococci comprises the following: groups, based on variants in the capsular polysaccharide; types, based on variants of the PorB outer membrane protein (OMP); subtypes, based on variants of the PorA OMP; and immunotypes, based on variants in the lipooligosaccharide (3). Within this scheme, PorA, also known as the class 1 OMP, is assigned the prefix "P1." followed by numbers, separated by commas, that correspond to the subtype designation (thus: P1.7,16). The two PorA variable regions (VR1 and VR2) that confer the subtypes are especially important

because they elicit bactericidal antibodies in humans (4). Consequently, a number of meningococcal vaccines under development contain the PorA protein as a major component (5).

Nucleotide sequence analyses of *porA* genes from multiple meningococcal isolates have established that the panel of serosubtyping monoclonal antibodies (MAbs) is not comprehensive. Meningococci are frequently only partially serosubtyped, and an increasing number of isolates are classified as non-serosubtypeable, either because a variant is not recognized by MAbs or because PorA is not expressed. This heterogeneous group of isolates can be fully characterized on the basis of their PorA VR1 and VR2 amino acid sequences deduced from nucleotide sequence data. To accommodate subtypes identified on the basis of sequence data alone, the scheme originally developed for MAb reactivity data (3) was modified so that VR families and variants were assigned on the basis of amino acid sequence relationships rather than their reactivity with specific MAbs. A distance matrix of all known VR1 and VR2 amino acid sequences was constructed, and VR amino acid sequences containing $\geq 80\%$ identity to each other were grouped into VR families. The VR epitope recognized by an existing MAb raised against PorA, or the first defined amino acid sequence of a VR family, was arbitrarily designated as the prototype VR for that particular family. Successive distinct members of a VR family were designated as minor variants of that family, and as such were sequentially assigned an additional unique lower case letter, e.g., P1.5a, P1.5b, P1.5c (6).

Although this nomenclature system was sufficiently flexible to accommodate both novel subtypes determined from nucleotide sequence analyses and those defined by the reactivity of specific MAbs, limitations have become apparent. First, while the 80% similarity rule has generally proved adequate to assign VR families, it is open to misinterpretation, leading to the inappropriate designation of VR sequences. Second, the assignment of minor variants within VR families is limited by the number of letters in the alphabet (7,8). We present a revised nomenclature, which addresses these issues and shows the relationship of

*University of Oxford, Oxford, United Kingdom; and †National Institute for Biological Standards and Control, South Mimms Potters Bar, United Kingdom

new designations to the previous designations and to the reactivities of the MAb panel. A database accessible through the Internet has been established, which will enable this scheme to be continually updated.

Materials and Methods

Bacterial Isolates

Two sets of meningococcal isolates were used for *porA* gene sequencing in this work. The first was a set of 393 isolates from cases of disease from diverse locations throughout the United Kingdom. These included 125 isolates from 1975; 100 isolates from 1985; 100 isolates from 1995; and 18 urethral isolates, provided by the Meningococcal Reference Unit, Manchester Public Health Laboratory, Manchester. Fifty isolates were provided by the Scottish Meningococcus and Pneumococcus Reference Laboratory, Glasgow. The second set of isolates included the 107 globally representative isolates obtained from both patients and carriers; these isolates were used to develop and evaluate the multilocus sequence typing isolate characterization scheme (9).

porA Gene Sequences and Validation

Nucleotide sequences of *porA* genes encoding the variants included in Appendix Tables 1 and 2 (online only; available from: http://www.cdc.gov/ncidod/EID/vol10no4/03-0247.htm_app.htm) were obtained from the literature or GenBank, determined by sequencing of polymerase chain reaction (PCR) products from the above isolates, or submitted by personal communication or to the PorA Web site. Where possible, sequences not determined in this study were validated by requesting sequence electropherograms from depositors. When electropherograms could not be resolved, isolates were requested and the *porA* genes resequenced. Seven sequences contained errors on resequencing original isolates and were therefore removed from the new nomenclature scheme. The deposited VR sequences used in this study were those submitted to the PorA Web site by June 11, 2001.

DNA Amplification and Nucleotide Sequence Determination of *porA*

Boiled meningococcal suspensions or DNA prepared from such suspensions with an Isoquick kit (Microprobe Corporation, Washington) were used as template to amplify the *porA* gene by using Taq Polymerase (Applied Biosystems, by Roche Molecular Systems Inc., Branchburg, NJ) with primers 210 and 211 (10). The amplification products were purified by precipitation with the addition of 0.6 V of 20% polyethylene glycol 8000/2.5M NaCl (11) and their nucleotide sequences determined at least once on each DNA strand. Sequence

reactions were carried out with primers 8L, 8U, 103L, 103U, 122L, 122U, 210, and 211 (10) using BigDye Ready Reaction Mix (Applied Biosystems) in accordance with the manufacturer's instructions. Unincorporated dye terminators were removed by precipitation of the termination products with the addition of 2.6 V of 96% ethanol and 115 mM sodium acetate. The reaction products were then separated and detected with an ABI Prism 377 automated DNA sequencer (PE Biosystems). Sequences were assembled from the resultant electropherograms with the STADEN suite of computer programs (12).

Manipulation and Alignment of Sequences

Sequences were manipulated in SeqLab, part of the GCG software package (13). All unique nucleotide sequences for each VR were aligned with reference to both the nucleotide and the amino acid sequences, such that all sequences remained in frame, gaps were minimized, and similar codons were aligned.

Identification of Families and Variants

To remain consistent with serologic and historical nomenclature, where a variant had been identified previously by serologic means, the identified sequence was used as a family prototype around which new sequences were grouped. An 80% amino acid identity cut-off—against the shortest sequence length when the sequences were of different length to allow for insertions, duplications, and deletions—was used as a guide in this grouping. In a few cases, a variant was assigned to a particular family even though the amino acid identity was slightly less than 80%, compared to the family prototype. In these cases, the new variant was still more similar to this particular family than to others but also contained a particular motif that was representative of family members. Therefore, a combination of overall similarity and presence of particular motifs was used to make the groupings. In a few cases, family-specific motifs were missing, but the sequences were otherwise identical or highly similar to members of the family. In such cases, the sequence was assigned as a variant of the family.

To further ensure that family groupings were consistent, the relationships among aligned nucleotide sequences encoding VR1 or VR2 were visualized by split decomposition analysis using SPLITSTREE version 3.1 (14). The split decomposition analysis was carried out in a sequential manner. In each analysis, a limited number of families were resolved, and the remaining variants were clustered together at a node. The variants that were resolved first were removed, and the analysis was repeated to resolve further families, and so on until all family groups were resolved (15). For analysis of the whole datasets, Hamming distances (equivalent to *p*-distance) were used

because some of the families were so diverse that using a substitution model was not possible. This method resolved the most distantly related families. The Kimura three parameter model (16) was used to determine whether related sequences constituted families.

A database and Web site containing all the assignments have been established (available from: <http://neisseria.org/nm/typing/pora>). The sequences are stored in a PostgreSQL database running on Linux. Perl scripts enable the database to be queried against either peptide or nucleotide sequences; when an identical match is not found, a BLAST search (17) can be performed to identify the nearest variant and family. Any length of sequence can be queried, enabling the variants to be quickly identified from a whole or partial gene sequence.

Results

Validation of Sequence Variants

The sequences defining the following subtypes in the previous nomenclature were not included in the new nomenclature as a consequence of the sequence validation: P1.2a, P1.2d, P1.5b, P1.10h, P1.10i, P1.10j, P1.18b, P1.19c, P1.24, P1.29.

Resolution of VR Families

The amino acid sequences of the prototype member of each of the VR families identified are shown aligned in Figures 1 and 2 together with corresponding nucleotide sequences. A total of 10 VR1 and 17 VR2 families were resolved. The most closely related VR families are VR2 P1.2 and VR2 P1.10, although the family prototypes are recognized by specific MAbs that are not cross-reactive. Both families start with a consensus amino acid sequence of HFVQ and end with PTLVP. They can be differentiated, however, by split decomposition where they cluster separately (15) and by certain motifs in their sequences. The P1.10 family members have a consensus motif QNKQNQ, with either the first or second triplet commonly repeated, while the P1.2 family members usually start with HFVQQ and commonly have variations of PQSQ or PKSQ. Grouped within the P1.2 family are four sequences that were previously designated as the P1.33 family. Like sequences in most of the P1.2 family members, these start with HFVQQ and, although they mostly end with SKPTLVP rather than SQPTLVP, they maintain the position of the serine residue.

Variation within Families

There was more variation within VR2 (161 unique variants) than in VR1 (73 unique variants). The variation in the VR families was mainly due to changes that could be ascribed to single nonsynonymous base changes. Although




Figure 1. Alignment of the amino acid and corresponding nucleotide sequence of each VR1 family "prototype." For a larger reproduction of this figure, see <http://www.cdc.gov/ncidod/EID/vol10no4/03-0247-G1.htm>

there may be minor differences in the relative contribution of nonsynonymous base changes and insertions or deletions between individual VR families, approximately twice as many variants have arisen as a result of point mutations than from any other type of mutation. The repetition of amino acid motifs or single residues was common within VR2. An example is the repetition of a threonine residue within the VR2 P1.13 family, where there are sequences with three to nine consecutive threonine residues.

Nomenclature Scheme

A consultation process was conducted by email among users of the PorA Web site and other interested parties. Several formats for a revised nomenclature were proposed and a request for alternatives made. The consensus opinion was to replace letters with numbers in subtype variant names in the following format: the prefix "P1." followed by the VR1 family name, followed by a dash and then the variant number, followed by a comma and the VR2 variant name in the same format. When a family prototype VR, or first sequence belonging to a family, was identified, no variant number was used; for example, a protein with VR1




Figure 2. Alignment of the amino acid and corresponding nucleotide sequence of each VR2 family "prototype." For a larger reproduction of this figure, see <http://www.cdc.gov/ncidod/EID/vol10no4/03-0247-G2.htm>

family 5 variant 3, and VR2 family 10 prototype would be written as: P1.5-3,10. This scheme was then used to rename all of the variants examined. The new names of variants are listed in online Appendix Tables 1 and 2, together with the previous nomenclature, peptide sequence, and source or reference. A database accessible through the Internet was established (available from: <http://neisseria.org/nm/typing/pora>).

Discussion

These analyses confirm that, while diverse, the VR1 and VR2 peptide sequences can be assigned to distinct meningococcal PorA variant sequence families. However, these regions of the PorA protein are likely to be exposed to continual selection imposed by host immune responses, and VR families might evolve over time into different families. The similarity of the P1.2 and P1.10 VR2 families is perhaps a consequence of relatively recent divergence of one VR family into two. Devising a scheme for defining the boundaries of VR families that accurately reflects the evolution of these regions is therefore not possible. Moreover, the high diversity of these sequences presents problems in developing a facile nomenclature. In revising the nomenclature system, we used amino acid sequences, deduced from nucleotide sequences, of the two VRs as the definition of subtype variants. The replacement of letters with numbers in subtype variant designations overcomes the shortage of letters but entails a change of name of variants.

Since MAbs are still routinely used globally for meningococcal serosubtyping, to avoid confusion, family names from the previous nomenclature were retained when possible, and especially when the family prototype was specifically recognized by a typing MAb. The new nomenclature builds on the previous designations but has the advantage of a limitless capacity for expanding the number of variants included. Retaining family names, when they can be shown to be reasonable, results in some minor changes to some family groupings. As meningococci evolve, the use of nucleotide sequencing to determine the VR peptide sequences will be increasingly important for epidemiologic studies and vaccine design, especially as the MAb panel gradually becomes less useful and sequencing technology becomes more available.

In the course of this study, a number of VR sequences that had been deposited previously in GenBank were found, when resequenced, to contain errors and were in fact previously identified variants. These sequences had been given new variant names and, in two cases, were sufficiently novel to warrant the naming of new families. The widespread use and, more importantly, the comparison of VR sequence data among different laboratories require consistency of nomenclature and a high level of data accuracy. One way to achieve this is through a central PorA database

in which sequence electropherograms are submitted for verification before new variant numbers are assigned. We have established a Web site for this role (available from: <http://neisseria.org/nm/typing/pora>). All known variants are listed, and a database query page is provided so that a VR sequence can be typed or pasted in and identified if previously seen. The Web site also includes links to the porB typing and MLST Web pages. The PorA Web site is now in widespread use by the research community and provides a single point of focus to ensure consistency in identifying and naming this important protein.

This work was funded by the Meningitis Research Foundation and the Wellcome Trust. M.C.J.M. is a Wellcome Trust Senior Research Fellow.

Dr. Russell is a scientist whose research interest is the molecular study of infectious disease agents.

References

- Pollard AJ, Maiden MCJ. Meningococcal disease. Totowa (NJ): Humana Press; 2001.
- Kuipers B, van den Dobbelen G, Wedege E, van Alphen L. Serological characterization. In: Pollard AJ, Maiden MC, editors. Meningococcal disease: methods and protocols. Totowa (NJ): Humana Press; 2001. p. 131-45.
- Frasch CE, Zollinger WD, Poolman JT. Serotype antigens of *Neisseria meningitidis* and a proposed scheme for designation of serotypes. Rev Infect Dis 1985;7:504-10.
- Martin SL, Borrow R, van der Ley P, Dawson M, Fox AJ, Cartwright KAV. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 2000;18:2476-81.
- Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002;359:1499-508.
- Suker J, Feavers IM, Achtman M, Morelli G, Wang J-F, Maiden MCJ. The *porA* gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation. Mol Microbiol 1994;12:253-65.
- Sacchi CT, Lemos APS, Brandt ME, Whitney AM, Melles CEA, Solari CA, et al. Proposed standardisation of *Neisseria meningitidis* PorA variable region typing nomenclature. Clin Diagn Lab Immunol 1998;5:845-55.
- Maiden MCJ, Russell J, Suker J, Feavers IM. *Neisseria meningitidis* subtype nomenclature. Clin Diagn Lab Immunol 1999;6:771-2.
- Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998;95:3140-5.
- Feavers IM, Maiden MCJ. A gonococcal *porA* pseudogene: implications for understanding the evolution and pathogenicity of *Neisseria gonorrhoeae*. Mol Microbiol 1998;30:647-56.
- Embley TM. The linear PCR reaction: a simple and robust method for sequencing amplified rRNA genes. Lett Appl Microbiol 1991;13:171-4.
- Staden R. The Staden sequence analysis package. Mol Biotechnol 1996;5:233-41.
- Womble DD. GCG: the Wisconsin Package of sequence analysis programs. Methods Mol Biol 2000;132:3-22.
- Huson DH. SplitsTree: analyzing and visualizing evolutionary data. Bioinformatics 1998;14:68-73.

15. Russell J. Variation in the PorA protein and clonal diversity within the UK *Neisseria meningitidis* population over a twenty year period (1975–1995). [doctoral thesis]. Oxford: The Open University; 2001.
16. Takahata N, Kimura M. A model of evolutionary base substitutions and its application with special reference to rapid change of pseudogenes. *Genetics* 1981;98:641–57.

Use of trade names is for identification only and does not imply endorsement by the Public Health Service or by the U.S. Department of Health and Human Services.

17. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* 1997;25:3389–402.

Address for correspondence: Janet Suker, Division of Bacteriology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms Potters Bar, EN6 3QG, United Kingdom; fax: [+44]-1707-663796; email: available from: <http://neisseria.org/nm/typing/pora>

EMERGING INFECTIOUS DISEASES

Tracking trends and analyzing new and reemerging infectious disease issues around the world

A peer-reviewed journal published by the National Center for Infectious Diseases

Vol. 5, No. 3, May–June 1999



Lyme Disease Vaccine

Antibiotics in Animal Feed

French Perspective

Search past issues of EID at www.cdc.gov/eid

Appendix Table 1. VR1 sequence nomenclature^a

Variant	Previous nomenclature	VR1 peptide sequence	Source or reference
5	5	PLQNIQPQVTKR	(1)
5-1	5a	PLQNIQQPQVTKR	(2,3)
Removed	5b	PALPNIQPQVTKA	(4)
5-2	5c	PLPNIQPQVTKR	(3)
5-3	5d	PLQNIKQPQVTKR	(5)
5-4	5e	PLQNIKQPQVTKR	(6)
5-5	-	PLQNIQPSVTKR	WS
5-6	-	LLQNIQQPQVTKR	WS
7	7	AQAANGGASGQVKVTKVTKA	(7)
7-1	7a	AQAANGGAGASGQVKVTKVTKA	(1)
7-2	7b	AQAANGGASGQVKVTKA	(3)
7-3	7c	AQAANGGARASGQVKVTKVTKA	(3)
7-4	7d	AQAANGGAGASGQVKVTKA	(3)
7-5	7e	AQAANGGAVASGQVKVTKVTKA	(5)
7-6	7f	AQAANGGASDQVKVTKA	GenBank AF146084
7-7	7g	AQSANGGASGQVKVTKVTKA	(6)
7-8	7h	AQAANGGAGASGQVKVTKVTKVTKA	(6)
7-9	7i	AQAANGGASGANGGASGQVKVTKA	This study
7-10	-	AQAANGGVSGQVKVTKVTKA	WS
7-11	-	AQAANGGASGQVKVTKVTKVTKA	WS
12	12	KLSSTNAKTGNKVEVTKA	(1)
12-1	12a	KPSSTNAKTGNKVEVTKA	(8)
12-2	12b	KPSSTKAKTGNKVEVTKA	(5)
12-3	12c	KPSSTNAKTGNKVKVTKA	WS
12-4	12d	KSSNTNAKTSNKVEVTKA	WS
12-5	12e	KPSSTNPKTGNKVEVTKA	(6)
12-6	12f	QPSNTNGKTGNKVEVTKA	(6)
12-7	-	KPSSTNANSSTNAKTGNKVEVTKA	WS
12-8	-	KPSSTNAKTSNEVEVTKA	WS
17	17	PPQKNQSQPVVTKA	(1)
17-1	17a	PPPKNQSQPVVTKA	This study
17-2	-	PPQKNQSQPLVTKA	WS
18	18	PPSKGQTGNKVTKG	(1)
18-1	18a	PPSQGQTGNKVTKG	(3)
Removed	18b	PPSKGQTAIKVTKA	(9)
18-2	18c	PPSKSQTGNKVTKG	This study
18-3	18d	PPSKGQTGNKVTKA	This study
18-4	18e	PPSKGQTGNKVIKG	GenBank AF162345
18-5	18f	PPSKGQVGNKVTKG	(6)
18-6	18g,32	QLSKGQVGNKVTKG	This study
18-7	18h,32a	QPSKGQVGNKVTKG	(8)
18-8	-	PPSKGQTGNKVVTNG	GenBank X81111
18-9	-	PPPKDQTGNKVTKG	WS
18-10	-	PPSEGQTGNTVTKA	WS
19	19	PPSKSQPVVTKA	(1)
19-1	19a	PPSKSQSQVTKA	(10)

19-2	19b	PPSKSQLQVKVTKA	GenBank Z14291
Removed	19c	PASKSQPQVKVTKA	(4)
19-3	19d	PRSKSQPQVKVTKA	(11)
19-4	19e	PPSNSQPQVKVTKA	(11)
19-5	19f	PLSKSQPQVKVTKA	(11)
19-6	19g	PPLKSQPQVKVTKA	(6)
19-7	19h	PSSKSQPQVKVTKA	(6)
19-8	19i	PPPKSQPQVKVTKA	WS
19-9	19j	PPSKSQPQVKVTQVKVTKA	WS
19-10	19k	PHSKSQPQVKVTKA	WS
19-11	-	PPRSQPQVKVTKA	(12)
19-12	-	PSSKSQSQVKVTKA	WS
19-13	-	PPSKSQTQVKVTKA	WS
19-14	-	PPSKSQHQVKVTKA	WS
20	20	QPQTANTQQGGKVKVTKA	(3)
21	21	QPQVTNGVQGNQVKVTKA	(3)
21-1	21a	QPNGVQGNQVKVTKA	This study
21-2	21b	QPQATNGVQGGQGNQVKVTKA	This study
21-3	21c	QPQVTKGVQGNQVKVTKA	WS
21-4	21d	QPQVPNGVQGNQVKVTKA	WS
21-5	21e	QPQVPNSVQGNQVKVTKA	WS
21-6	-	QPQATNGVQGGRQGNQVTVTKA	(8)
21-7	-	QLQVTNGVQGNQVKVTKA	WS
22	22	QPSKAQGQTNNQVKVTKA	(1)
22-1	22a	QPSRTQGQTSNQVKVTKA	(8,13)
22-2	22b	QPSRTQAQTSNQVKVTKA	This study
22-3	22c	QPSKAKGQTNNQVKVTKA	WS
22-4	22d	QLSKAQGQTNNQVKVTKA	WS
22-5	-	QPSKAQGQTNNQVKVTKR	WS
Removed	29	PAPKYSTTQVTKA	(4)
31	31	PPSSNQGKNQAQTGNTVTKA	This study

^aSequences that have been removed were the result of sequencing errors in the original research. WS, Web site submission.

Appendix References

1. Maiden MCJ, Suker J, McKenna AJ, Bygraves J, Feavers IM. [Comparison of the class 1 outer membrane proteins of eight serological reference strains of *Neisseria meningitidis*](#). Mol Microbiol 1991;5:727–36.
2. Van der Ley P, Heckels JE, Virji M, Hoogerhout P, Poolman JT. [Topology of outer membrane porins in pathogenic *Neisseria* spp.](#) Infect Immun 1991;59:2963–71.
3. Suker J, Feavers IM, Achtman M, Morelli G, Wang J-F, Maiden MCJ. [The *porA* gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation](#). Mol Microbiol 1994;12:253–65.
4. Brooks JL, Fallon RJ, Heckels JE. [Sequence variation in class 1 outer membrane protein in *Neisseria meningitidis* isolated from patients with meningococcal infection and close household contacts](#). FEMS Microbiol Lett 1995;128:145–50.

5. Arhin FF, Moreau F, Coulton J, Mills EL. [Sequencing of *porA* from clinical isolates of *Neisseria meningitidis* defines a subtyping scheme and its genetic regulation.](#) Can J Microbiol 1998;44:56–63.
6. Sacchi CT, Whitney AM, Popovic T, Beall DS, Reeves MW, Plikaytis BD, et al. [Diversity and prevalence of PorA types in *Neisseria meningitidis* serogroup B in the United States, 1992-1998.](#) J Infect Dis 2000;182:1169–76.
7. McGuinness B, Barlow AK, Clarke IN, Farley JE, Anilionis A, Poolman JT, et al. [Deduced amino acid sequences of class 1 protein \(PorA\) from three strains of *Neisseria meningitidis*.](#) J Exp Med 1990;171:1871–82.
8. Sacchi CT, Lemos APS, Brandt ME, Whitney AM, Melles CEA, Solari CA, et al. [Proposed standardisation of *Neisseria meningitidis* PorA variable region typing nomenclature.](#) Clin Diagn Lab Immunol 1998;5:845–55.
9. McGuinness BT, Lambden PR, Heckels JE. [Class 1 outer membrane protein of *Neisseria meningitidis*: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology.](#) Mol Microbiol 1993;7:505–14.
10. Feavers IM, Fox AJ, Gray S, Jones DM, Maiden MCJ. [Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design.](#) Clin Diagn Lab Immunol 1996;3:444–50.
11. Wedege E, Caugant DA, Musacchio A, Saunders NB, Zollinger WD. [Redesignation of a purported P1.15 subtype-specific meningococcal monoclonal antibody as a P1.19-specific reagent.](#) Clin Diagn Lab Immunol 1999;6:639–42.
12. Sacchi CT, Lemos AP, Popovic T, Cassio de Moraes J, Whitney AM, et al. [Serosubtypes and PorA types of *Neisseria meningitidis* serogroup B isolated in Brazil during 1997–1998: overview and implications for vaccine development.](#) J Clin Microbiol 2001;39:2897–903.
13. Maiden MCJ, Bygraves JA, McCarvil J, Feavers IM. [Identification of meningococcal serosubtypes by polymerase chain reaction.](#) J Clin Microbiol 1992;30:2835–41.
14. Bart A, Dankert J, van der Ende A. [Antigenic variation of the class I outer membrane protein in hyperendemic *Neisseria meningitidis* strains in the Netherlands.](#) Infect Immun 1999;67:3842–6.
15. Suker J, Feavers IM, Maiden MCJ. [Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: implications for serological typing and vaccine design.](#) Microbiology 1996;142:63–9.
16. Wedege E, Kolberg J, Delvig A, Hoiby EA, Holten E, Rosenqvist E, et al. [Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway.](#) Clin Diagn Lab Immunol 1995;2:314–21.
17. Saunders NB, Brandt BL, Warren RL, Hansen BD, Zollinger WD. [Immunological and molecular characterization of three variant subtype P1.14 strains of *Neisseria meningitidis*.](#) Infect Immun 1998;66:3218–22.
18. Feavers IM, Heath AB, Bygraves JA, Maiden MCJ. [Role of horizontal genetic exchange in the antigenic variation of the class 1 outer membrane protein of *Neisseria meningitidis*.](#) Mol Microbiol 1992;6:489–95.

Appendix Table 2. VR2 sequence nomenclature^a

Variant	Previous nomenclature	VR2 peptide sequence	Source or reference
1	1	YVAVENGVAKKVA	(1)
1-1	1a	YVAVENGATKKVA	(6)
1-2	1b	YVAVENGVVKKVA	This study
1-3	1c	YVAVENGVAKKVT	WS
2	2	HFVQQTPKSQPTLVP	(1)
-	2a	found to be 2e	(1)
2-1	2b	HFVQQPPKSQPTLVP	(10)
2-2	2c	HFVQQTPQSQPTLVP	(3)
Removed	2d	HFVQETPKSQPTLVP	(4)
2-3	2e	HFVQQPPKSQPTLVP	This study
2-4	2f	HFVQQTPQSRPTLVP	This study
2-5	2g	HFVQQIPQSQPTLVP	WS
2-6	2i	HFVQQTPTLVP	(6)
2-7	-	HFVQQTSKSKPTLVP	WS
2-8	-	HFVQQTTKSKPTLVP	WS
2-9	-	HFVQQTPQSKPTLVP	WS
2-10	-	HFVQQAPQSQSTLVP	WS
2-11	-	HFVLQTPQSQPTLVP	WS
2-12	-	HFVQQIPKSQPTLVP	WS
2-13	-	YFVQQTPQSQPTLVP	GenBank AF239810
2-14	33	HFVQQKLASKPTLVP	WS
2-15	33a	HFVQQKSTSKPTLVP	WS
2-16	33b	HFVQQKPTSKPTLVP	WS
2-17	33c	HFVQQQPTSEPTLVP	WS
2-18	-	HFVQQIPKSPILVP	WS
2-19	-	HFVQQTSQSQPTLVP	WS
2-20	-	HFVQQTPIVQQTPKSQPTLVP	WS
3	3	TLANGANNTIIRVP	(3)
3-1	3a	TVANGANNTIIRVP	(14)
3-2	3b	TLANGANDTIIRVP	This study
3-3	-	TLANGADNTIIRVP	WS
3-4	-	TPANGANNTIIRVP	WS
3-5	-	TLAKGANNTIIRVP	WS
4	4	HVVVNKNVATHVP	(13)
4-1	4a	HVVVNKNVATHVP	(8)
4-2	4b	HVVVNKNVATHVPAKVATHVP	This study
4-3	4c	HVVVNKNVTTHVP	WS
9	9	YVDEQSKYHA	(1)
9-1	9a	YVDSKYHA	GenBank AF148643
9-2	-	YVGEQSKYHA	WS
9-3	-	YVDEQSKDHA	WS
9-4	-	YVDKQSKYHA	WS
9-5	-	YVDEQSEYHA	WS
10	10	HFVQNKQNRPTLVP	(3)
10-1	10a	HFVQNKQNPPTLVP	(10,15)

10-2	10b	HFVQDKKGQPPTLVP	(10,15)
10-3	10c	HFVQNKQNQPPTLVP	(10,15)
10-4	10d	HFVQNKQNKQNQPPTLVP	(10,15)
10-5	10e	HFVQNKQSQRPPTLVP	(3)
10-6	10f	HFVQNKQNQQNQQNQPPTLVP	(10,15)
10-7	10g	HFVQNKQNKPPPTLVP	(10,15)
Removed	10h		(4)
Removed	10i		(4)
Removed	10j		(4)
10-8	10k	HFVQNKQNQQNQPPTLVP	This study
10-9	10l	HFVQNKQNKQNQLPTLVP	This study
10-10	10m	HFVQNKQNKQNQNQPPTLVP	This study
10-11	10n	HFVQNKQNQRSTLVP	This study
10-12	10o	HFVQNKQNQLPTLVP	GenBank AF182278
10-13	10p	HFVQNKQNKKNQPPTLVP	WS
10-14	10q	HFVQNKQHQPPTLVP	WS
10-15	10r	HFVQNKQNQPSTLVP	WS
10-16	10s	HFVQNKQNQWSTLVP	WS
10-17	10t	HFVQNKQNQTPTLVP	WS
10-18	10u	HFVQNKQSQPPTLVP	WS
10-19	10w	HFVQNKQNKQKQPPTLVP	(6)
10-20	10i,10v	HFVQNKQNQWLTLP	GenBank AF162346
10-21	10x	HFVPDKKGQPPTLVP	(6)
10-22	10y	HFVQNKQNKQNQQNQPPTLVP	WS
10-23	-	HFVQNKQNQWPTLVP	WS
10-24	-	HFVKNKQNQRPTLVP	(6)
10-25	-	HFVQDKKGQP	WS
13	13	YWTTVNTGSATTTTTFVP	(16)
13-1	13a	YWTTVNTGSATTTTTFVP	(3)
13-2	13b	YWTTVNTGSATTTTTFVP	(16)
13-3	13c	YWTTVNTGSATITTFVP	(10)
13-4	13d	YYTTVTQGSATTTTTFVP	(10)
13-5	13e	YWTTVNTGSATTTTTTTTTFVP	(16)
13-6	13f	YWTTVNTGSATTTTTTTTTFVP	(5)
13-7	13g	YWTTVNTGSATTTTTTFVP	(5)
13-8	13h	YWITVNTGSATTTTTFVP	(16)
13-9	13i	YWTTVNTGSATTFVP	This study
13-10	13j	YWTTVNTGSVTTTTFVP	WS
13-11	13k	YWTTVNTGSAATTTTTFVP	This study
13-12	-	YWTAVNAGSATTTTTFVP	WS
14	14	YVDEKKMVHA	(13)
14-1	14a	YVDEKKKMVHA	(8)
14-2	14b	YVDEKKKVHA	(17)
14-3	14c	YVDEKNMVHA	(17)
14-4	14d	YVDENKMVHA	(11)
14-5	14e	YVDKEQVSHA	This study
14-6	14f	YVDEKQVSHA	This study
14-7	14g	YVDETKMVHA	WS
14-8	-	YVDEKRMVHA	WS
14-9	-	YVDAKKMVHA	WS
15	15	HYTRQNNADVFP	(1)
15-1	15a	HYTRQNNTDVFVP	(7)

15-2	15c	HYTRQNNNTDVFVP	This study
15-3	15d	HYTRPNNTDVFVP	(11)
15-4	15e	HYNTRQNNADVFP	WS
15-5	15f	HYTRQNSADVFP	This study
15-6	15g	HYTRQNYADVFP	WS
15-7	15h	HYTRQNNANVFVP	(6)
15-8	-	HYTRQNNAGVFVP	(12)
15-9	-	HYTRQNNTRQNNADVFP	(12)
15-10	-	HYTGQNNADVFP	(12)
15-11	15b	HYTRQNNIDVFVP	(10)
15-12	-	HYNTRQNNIDVFVP	WS
15-13	-	HYTRQNNQNNIDVFVP	WS
15-14	-	HYTNTRQNNIDVFVP	WS
15-15	-	HYTRQSNTDVFVP	WS
15-16	-	HYTRQNNADVFP	WS
16	16	YYTKDTNNNLTLP	(1)
16-1	16w	YYTKGKNNALTLVP	WS
16-2	16b	YYTKNTNNNLTLP	(18)
16-3	16c	YYTKDKNDNLTLP	(5)
16-4	16d	YYTKDKNDKLTLP	(5)
16-5	16e	YYTKDTNNNNLTLP	(5)
16-6	16f	YYTKHTNNNLTLP	This study
16-7	16g	YYTKDTNTKDTNNNLTLP	This study
16-8	16h	YYTKDKNNALTLVP	(6)
16-9	16i	YYTKDTNDLTLP	WS
16-10	16j	YYTNNNLTLP	This study
16-11	16k	YYTDTNNNLTLP	This study
16-12	16l	YYTKDTNDNLTLP	This study
16-13	16m	YYTEDTNNNLTLP	WS
16-14	16n	YYTKDTNTNLTLP	WS
16-15	16p	YYNTKDTNNNLTLP	This study
16-16	16q	YYTKDTNNNPTLP	This study
16-17	16r	YYTKDTNNTNNNLTLP	(6)
16-18	16s	YYTKDTNTNNNLTLP	GenBank AF143744
16-19	16t	YYTKDTNNNLHTKDTNNNLTLP	(6)
16-20	16u	KDTNNNLTLP	(6)
16-21	16v	YYTKDTKNNLTLP	(6)
16-22	-	YYTKDTNNILTLP	WS
16-23	-	YYTKDNKNDNLTLP	(6)
16-24	-	YYTKVENDNLTLP	WS
16-25	-	YYTKDTNNNLNLTLP	WS
16-26	-	YYTNTNNNLTLP	WS
16-27	-	YYTKDTNNNLTLP	WS
23	23	HWNTVYNTNGTTTTFVP	(3)
23-1	23a	HWNTVYNTNGTTTTTTTFVP	(6)
23-2	-	HWNTVYNTNGTTTTTFVP	WS
Removed	24	TLANVANTNIGVP	(13)
25	25	TYTVDSSGVVTPVP	(1)
25-1	25a	TYTVDSSGVFTPVP	This study
25-2	25b	TYTEGSSGVFTPVP	WS
25-3	25c	TYTVDSSGVVTPLP	WS
25-4	25d	TYTVGSRDVVTPVP	GenBank AF162345

25-5	25e	TYTVDSNNVVTPVP	GenBank AF157834
25-6	25f	TYTVDSGVVTPVP	(6)
25-7	25g	YTVDSGGVVTPVP	WS
25-8	-	TYTVDSGGVP	WS
25-9	-	TYTVDNSSVVTPVP	WS
26	26	HFVADSQKTRVP	(10)
26-1	26a	HFVADSQGEITRVP	GenBank AF146084
26-2	-	YFTADPNDQNKITRVP	WS
28	28	YYTTATNSSTSTTFVP	(10)
30	30	HYTTVYNATTTTTTFVP	WS
30-1	30a	HYTTVYNATTTTTTFVP	This study
30-2	30b	HYTTVYNATTTTTTFVP	(6)
30-3	30c	HYTTVYNATTTTTTFVP	This study
30-4	30d	HYTTVYNATTTTTTFVP	WS
30-5	30e	HYTTVYNATTTTTTFVP	WS
34	34	YVDDQKVKGP	(6)
34-1	-	YVDDQKVKGP	WS
35	-	TFTLESNQMKPVP	WS

Appendix References

1. Maiden MCJ, Suker J, McKenna AJ, Bygraves J, Feavers IM. [Comparison of the class 1 outer membrane proteins of eight serological reference strains of *Neisseria meningitidis*](#). Mol Microbiol 1991;5:727–36.
2. Van der Ley P, Heckels JE, Virji M, Hoogerhout P, Poolman JT. [Topology of outer membrane porins in pathogenic *Neisseria* spp.](#) Infect Immun 1991;59:2963–71.
3. Suker J, Feavers IM, Achtman M, Morelli G, Wang J-F, Maiden MCJ. [The *porA* gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation](#). Mol Microbiol 1994;12:253–65.
4. Brooks JL, Fallon RJ, Heckels JE. [Sequence variation in class 1 outer membrane protein in *Neisseria meningitidis* isolated from patients with meningococcal infection and close household contacts](#). FEMS Microbiol Lett 1995;128:145–50.
5. Arhin FF, Moreau F, Coulton J, Mills EL. [Sequencing of *porA* from clinical isolates of *Neisseria meningitidis* defines a subtyping scheme and its genetic regulation](#). Can J Microbiol 1998;44:56–63.
6. Sacchi CT, Whitney AM, Popovic T, Beall DS, Reeves MW, Plikaytis BD, et al. [Diversity and prevalence of PorA types in *Neisseria meningitidis* serogroup B in the United States, 1992-1998](#). J Infect Dis 2000;182:1169–76.
7. McGuinness B, Barlow AK, Clarke IN, Farley JE, Anilionis A, Poolman JT, et al. [Deduced amino acid sequences of class 1 protein \(PorA\) from three strains of *Neisseria meningitidis*](#). J Exp Med 1990;171:1871–82.
8. Sacchi CT, Lemos APS, Brandt ME, Whitney AM, Melles CEA, Solari CA, et al. [Proposed standardisation of *Neisseria meningitidis* PorA variable region typing nomenclature](#). Clin Diagn Lab Immunol 1998;5:845–55.

9. McGuinness BT, Lambden PR, Heckels JE. [Class 1 outer membrane protein of *Neisseria meningitidis*: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology.](#) Mol Microbiol 1993;7:505–14.
10. Feavers IM, Fox AJ, Gray S, Jones DM, Maiden MCJ. [Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design.](#) Clin Diagn Lab Immunol 1996;3:444–50.
11. Wedege E, Caugant DA, Musacchio A, Saunders NB, Zollinger WD. [Redesignation of a purported P1.15 subtype-specific meningococcal monoclonal antibody as a P1.19-specific reagent.](#) Clin Diagn Lab Immunol 1999;6:639–42.
12. Sacchi CT, Lemos AP, Popovic T, Cassio de Morais J, Whitney AM, et al. [Serosubtypes and PorA types of *Neisseria meningitidis* serogroup B isolated in Brazil during 1997–1998: overview and implications for vaccine development.](#) J Clin Microbiol 2001;39:2897–903.
13. Maiden MCJ, Bygraves JA, McCarvil J, Feavers IM. [Identification of meningococcal serosubtypes by polymerase chain reaction.](#) J Clin Microbiol 1992;30:2835–41.
14. Bart A, Dankert J, van der Ende A. [Antigenic variation of the class I outer membrane protein in hyperendemic *Neisseria meningitidis* strains in the Netherlands.](#) Infect Immun 1999;67:3842–6.
15. Suker J, Feavers IM, Maiden MCJ. [Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: implications for serological typing and vaccine design.](#) Microbiology 1996;142:63–9.
16. Wedege E, Kolberg J, Delvig A, Hoiby EA, Holten E, Rosenqvist E, et al. [Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway.](#) Clin Diagn Lab Immunol 1995;2:314–21.
17. Saunders NB, Brandt BL, Warren RL, Hansen BD, Zollinger WD. [Immunological and molecular characterization of three variant subtype P1.14 strains of *Neisseria meningitidis*.](#) Infect Immun 1998;66:3218–22.
18. Feavers IM, Heath AB, Bygraves JA, Maiden MCJ. [Role of horizontal genetic exchange in the antigenic variation of the class 1 outer membrane protein of *Neisseria meningitidis*.](#) Mol Microbiol 1992;6:489–95.